<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04794842</url>
  </required_header>
  <id_info>
    <org_study_id>Tetracaine_vs_Phenol</org_study_id>
    <nct_id>NCT04794842</nct_id>
  </id_info>
  <brief_title>Comparing Topical Tetracaine Drops to Topical Focal Phenol for Local Anesthesia During Intratympanic Steroid Injection</brief_title>
  <official_title>Comparing Topical Tetracaine Drops to Topical Focal Phenol for Local Anesthesia During Intratympanic Steroid Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Our Lady of the Lake Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Louisiana State University Health Sciences Center - New Orleans</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Our Lady of the Lake Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intratympanic steroid injections are an accepted treatment for Meniere's disease and&#xD;
      idiopathic sudden sensorineural hearing loss. This treatment is typically performed using&#xD;
      local topical anesthesia. There is very limited research on the differences of medications&#xD;
      and application procedures effect on patients' pain during the procedure.Topical Tetracaine&#xD;
      solution and topical phenol have been shown to be effective as local anesthesia for the&#xD;
      tympanic membrane when used for myringotomy. Currently there is no consensus on medication&#xD;
      and technique however focally applied phenol is the more widely used technique. We believe&#xD;
      this study can provide valuable information given the disadvantages of topical phenol&#xD;
      including burning upon application as well as possible increase in persistent tympanic&#xD;
      membrane perforation. The objectives are to determine the effectiveness of tetracaine drops&#xD;
      for local anesthesia for intratympanic steroid injections compared to focal topical phenol&#xD;
      application and to identify if tetracaine drops provides adequate anesthesia for&#xD;
      intratympanic steroid injection with less pain on application than focal phenol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single-Blinded Randomized Cohort</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Intervention choice blinded to the patient</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Pain Score</measure>
    <time_frame>Immediately following the procedure to 6 months from procedure</time_frame>
    <description>Evaluate any differences in pain scores assessed pre/post intervention and between the two topical anesthetics used prior to the intratympanic steroid injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Statistical difference in tympanic membrane perforation presence or absence after the steroid injection procedure when using either tetracaine or phenol as the local anesthetic</measure>
    <time_frame>Immediately following the procedure to 6 months from procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Intratympanic Steroid Injection</condition>
  <condition>Idiopathic Sudden Sensorineural Hearing Loss</condition>
  <condition>Meniere Disease</condition>
  <arm_group>
    <arm_group_label>Tetracaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be positioned in supine position at this time 0.5% tetracaine drops will be used to fill the ear canal. Tetracaine will then be allowed to stay in place for approximately 10 to 15 minutes with the patient's head positioned with affected ear up. After this, using an operative microscope the drops will be removed from the ear canal with suction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be positioned in supine position and tympanic membrane visualized with operative microscope. Phenol applicator will be used to topically apply 90% phenol to the injection site (posterior/Inferior aspect of tympanic membrane).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracaine 5% drops</intervention_name>
    <description>same as information in the arm/group description</description>
    <arm_group_label>Tetracaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenol 90% concentration</intervention_name>
    <description>same as information in the arm/group description</description>
    <arm_group_label>Phenol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult subjects (18 years of age or greater)&#xD;
&#xD;
          -  Diagnosed with Idiopathic Sudden Sensorineural hearing loss or Meniere's disease&#xD;
&#xD;
          -  Care plan includes treatment via intratympanic steroid injection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Having a current tympanic membrane perforation&#xD;
&#xD;
          -  Adults unable to sign written consent&#xD;
&#xD;
          -  Individuals less than 18 years of age&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leslie S Son, PhD</last_name>
    <phone>2257574165</phone>
    <email>Lson@lsuhsc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine LeBeouf, DNP</last_name>
    <phone>2257655956</phone>
    <email>christine.leboeuf@fmolhs.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Our Lady of the Lake Hospital</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Son, Ph.D.</last_name>
      <phone>225-757-4165</phone>
      <email>lson@lsuhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christine LeBoeuf, DNP</last_name>
      <phone>225-765-5956</phone>
      <email>christine.leboeuf@fmolhs.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Filipo R, Attanasio G, Russo FY, Viccaro M, Mancini P, Covelli E. Intratympanic steroid therapy in moderate sudden hearing loss: a randomized, triple-blind, placebo-controlled trial. Laryngoscope. 2013 Mar;123(3):774-8. doi: 10.1002/lary.23678. Epub 2013 Feb 1.</citation>
    <PMID>23378346</PMID>
  </reference>
  <reference>
    <citation>Wu HP, Chou YF, Yu SH, Wang CP, Hsu CJ, Chen PR. Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otol Neurotol. 2011 Jul;32(5):774-9. doi: 10.1097/MAO.0b013e31821fbdd1.</citation>
    <PMID>21646929</PMID>
  </reference>
  <reference>
    <citation>Leng Y, Liu B, Zhou R, Liu J, Liu D, Zhang SL, Kong WJ. Repeated courses of intratympanic dexamethasone injection are effective for intractable Meniere's disease. Acta Otolaryngol. 2017 Feb;137(2):154-160. doi: 10.1080/00016489.2016.1224920. Epub 2016 Sep 21.</citation>
    <PMID>27650470</PMID>
  </reference>
  <reference>
    <citation>McRackan TR, Best J, Pearce EC, Bennett ML, Dietrich M, Wanna GB, Haynes DS, Labadie RF. Intratympanic dexamethasone as a symptomatic treatment for Ménière's disease. Otol Neurotol. 2014 Oct;35(9):1638-40. doi: 10.1097/MAO.0000000000000500.</citation>
    <PMID>25188506</PMID>
  </reference>
  <reference>
    <citation>Belhassen S, Saliba I. Pain assessment of the intratympanic injections: a prospective comparative study. Eur Arch Otorhinolaryngol. 2012 Dec;269(12):2467-73. doi: 10.1007/s00405-011-1897-z. Epub 2011 Dec 28.</citation>
    <PMID>22203120</PMID>
  </reference>
  <reference>
    <citation>Silverstein H, Call DL. Tetracaine base. An effective surface anesthetic for the tympanic membrane. Arch Otolaryngol. 1969 Aug;90(2):150-1.</citation>
    <PMID>5794873</PMID>
  </reference>
  <reference>
    <citation>Kumar R, Banerjee A. Myringotomy and ventilation tube insertion with minims tetracaine drops. Eur Arch Otorhinolaryngol. 2011 Oct;268(10):1533-4. doi: 10.1007/s00405-011-1654-3. Epub 2011 Jun 17.</citation>
    <PMID>21681571</PMID>
  </reference>
  <reference>
    <citation>Hoffman RA, Li CL. Tetracaine topical anesthesia for myringotomy. Laryngoscope. 2001 Sep;111(9):1636-8.</citation>
    <PMID>11568619</PMID>
  </reference>
  <reference>
    <citation>Robertson A, Whitwell R, Osborne J. Is phenol a safe local anaesthetic for grommet insertion? J Laryngol Otol. 2006 Jan;120(1):20-3.</citation>
    <PMID>16375777</PMID>
  </reference>
  <reference>
    <citation>Weisskopf A. Phenol anesthesia for myringotomy. Laryngoscope. 1983 Jan;93(1):114.</citation>
    <PMID>6823169</PMID>
  </reference>
  <reference>
    <citation>Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S240-52. doi: 10.1002/acr.20543. Review.</citation>
    <PMID>22588748</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Our Lady of the Lake Hospital</investigator_affiliation>
    <investigator_full_name>Leslie Son</investigator_full_name>
    <investigator_title>Academic Research Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Hearing Loss, Sensorineural</mesh_term>
    <mesh_term>Meniere Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenol</mesh_term>
    <mesh_term>Tetracaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

